

ER 12345678 Pgt-2, 71B30 Fifth U.S. Army Control Group (Delayed) Headquarters, Fifth U.S. Army, Chicago, Ill. 60615.

Temporary Duty to: _____
Reporting date (TDY): _____
Effective (TDY): _____
Assigned to: 00000, U.S. Army Reception Station, Fort Knox, Ky., for further assignment.

Date of Rank: _____
Home of Record: 14 Walston Place, Battleground, Ind. 30315.

Current Location: (Orders address) 420 Montclair Street, St. Louis, Mo. 63132.

Period: 00 months and 00 days.

Authority: P.L. 89-587, DA Circular 135-10.

Accounting Classification: (See AR 37-100).

Permanent Change of Station (Movement Designator Code): _____

Procurement Program Number: 00.

Effective Date of Change of Strength Accountability: July 8, 1967.

Special Instructions:

On the EDCSA you are relieved from your present Reserve Unit or Control Group.

Reception Station will use orders format TC 250 (AR 310-10) for further assignment. Government transportation request and meal tickets (as appropriate) will be furnished upon the member's request.

The term of enlistment of member concerned is extended as necessary to permit completion of the period of active duty for which order and/or served.

U.S. Army Reception Station Commanders will determine medical fitness, if required, in accordance with Chapter 3, AR 40-501. Those medically unfit will be processed in accordance with AR 835-200.

For the Adjutant General.

J. W. HURD,

Colonel, AGC, Comptroller, TAGO.

[P.R. Doc. 67-12780; Filed, Oct. 30, 1967; 8:45 a.m.]

DEPARTMENT OF HEALTH, EDUCATION, AND WELFARE

Food and Drug Administration

CANNED MUSHROOMS DEVIATING FROM IDENTITY STANDARD

Notice of Modification of Temporary Permit for Market Testing

Notice was given in the *FEDERAL REGISTER* of May 2, 1967 (32 F.R. 6737), that a temporary permit had been issued to Oxford Royal Mushroom Products, Inc., Kelson, Pa. 19346. The permit, granted pursuant to (21 CFR 10.5), covered interstate marketing tests of canned mushrooms in the button and whole forms with added calcium disodium EDTA, an ingredient not provided

For non-MOS qualified members. When member is MOS qualified response will be extended to indicate the unit, training activity, or service school as shown in DA assignment instructions.

Delete when orders address is shown at end of orders.

Period of active duty will be for 24 months less any previous period of active and/or active duty for training.

for by the standard of identity for this canned vegetable (21 CFR 51.990).

Notice is hereby given that the subject temporary permit has been modified to include the optional forms of "pieces and stems" and "sliced" canned mushrooms under the same terms and conditions of the permit now in effect.

The expiration date of the permit (Apr. 24, 1968) is unchanged.

Dated: October 25, 1967.

J. K. KIRK,

Associate Commissioner
for Compliance.

[P.R. Doc. 67-12799; Filed, Oct. 30, 1967; 8:47 a.m.]

[Docket No. FDC-D-103]

DRUGS FOR HUMAN USE CONTAINING BITHIONOL

Notice of Withdrawal of Approval of New-Drug Applications

Rexall Drug Co.; Medical Arts Supply Co.; Shulton, Inc.; Huntington Laboratories, Inc.; West Chemical Products, Inc.; North Coast Chemical Co.; Armour & Co.; Purex Corp.

In the *FEDERAL REGISTER* of July 19, 1967 (32 F.R. 10615), the Commissioner of Food and Drugs issued a Notice of Opportunity for Hearing on his proposal to issue an order under the provisions of section 505(e) (21 U.S.C. 355(e)) of the Federal Food, Drug, and Cosmetic Act (1) withdrawing approval of new-drug application No. 12-268 and all amendments and supplements thereto held by the Purex Corp. for the drug Cutitane Acne Cream, which contains bithionol as an active ingredient, and (2) withdrawing approval of all other new-drug applications and all amendments and supplements thereto for drugs for human use containing any bithionol, for which applicants have waived opportunity for a hearing on the proposal.

Each holder of the new-drug applications listed below has by letter requested withdrawal of approval of his application for a drug containing bithionol, and thereby waived notice of hearing as provided by section 505 of the act (21 U.S.C. 355) and the regulations thereunder (21 CFR Part 130), prior to such withdrawal:

A. NDA No. 8-982 for Rexall Medicated Dusting Powder, held by Rexall Drug Co., 8480 Beverly Boulevard, Los Angeles, Calif. 90054.

B. NDA No. 8-178 for Surginol Surgical Soap, held by Medical Arts Supply Co., 706-08-10 Fourth Avenue, Huntington, W. Va. 25701.

C. NDA No. 9-233 for Thylox Sulfur Cream and Thylox Sulfur Soap with Actamer, held by Shulton, Inc., Route 46, Clifton, N.J. 07011.

D. NDA No. 9-240 for Degerm with Actamer, held by Huntington Laboratories, Inc., 970 East Tipton Street, Huntington, Ind. 46750.

E. NDA No. 9-254 for Lan-O-Kleen, held by West Chemical Products, Inc.,

42-16 West Street, Long Island City, N.Y. 11101.

F. NDA No. 9-287 for Coco-Borax Powdered Hand Soap, held by North Coast Chemical Co., 6300 17th Avenue, South, Seattle, Wash. 98108.

G. NDA No. 10-935 for Dial Deodorant Soap, held by Armour Grocery Products Division of Armour & Co., 1355 West 31st Street, Chicago, Ill. 60609.

H. NDA No. 12-268 for Cutitane Acne Cream, held by Purex Corp., 24600 South Main Street, Wilmington, Calif. 90746.

The Commissioner of Food and Drugs, by virtue of the authority vested in the Secretary of Health, Education, and Welfare by the provisions of the act (sec. 505(e), 52 Stat. 1053; 21 U.S.C. 355(e)) and delegated to him by the Secretary (21 CFR 2.120), finds on the basis of new evidence of clinical experience not contained in the above-identified new-drug applications or not available to the Commissioner until after such applications were approved, and tests by methods not deemed reasonably applicable when such applications were approved, evaluated together with the evidence available when the said applications were approved, that the bithionol-containing drugs, Rexall Medicated Dusting Powder under NDA No. 8-982, Surginol Surgical Soap under NDA No. 9-178, Thylox Sulfur Cream and Thylox Sulfur Soap with Actamer under NDA No. 9-233, Degerm with Actamer under NDA No. 9-240, Lan-O-Kleen under NDA No. 9-254, Coco-Borax Powdered Hand Soap under NDA No. 9-287, Dial Deodorant Soap under NDA No. 10-935, and Cutitane Acne Cream under NDA No. 12-268, are not shown to be safe for use under the conditions of use upon the basis of which these applications were approved.

The Commissioner further finds that clinical experience and the use of photopatch tests show that the use of bithionol, a component of each drug listed above, may cause photosensitivity and that in some instances the photosensitization may persist for prolonged periods as severe reactions without further contact with sensitizing articles and, further, that bithionol may produce cross photosensitization with other commonly used chemicals such as certain halogenated salicylanilides and hexachlorophene.

Therefore, based on the foregoing findings of fact, the approval of the new-drug applications listed above for the articles named is withdrawn, effective on the date of signature of this document. Upon promulgation of this order, all drugs for human use containing any bithionol will be regarded as new drugs for which no approval is in effect.

Dated: October 24, 1967.

JAMES L. GODDARD,

Commissioner of Food and Drugs.

[P.R. Doc. 67-12800; Filed, Oct. 30, 1967; 8:47 a.m.]